Stock GILD34 GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Gilead Sciences, Inc. Sao Paulo

Equities

GILD34

BRGILDBDR000

Market Closed - Sao Paulo
Other stock markets
 18:51:12 10/05/2024 BST 		5-day change 1st Jan Change
169.9 BRL -1.92% Intraday chart for Gilead Sciences, Inc. +3.77% -11.73%
05-07 Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
05-02 UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
BU
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
BU
Gilead Sciences to Present at Upcoming Investor Conferences
BU
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
BU
Gilead: Q1 Earnings Snapshot
AQ
Gilead Sciences Announces First Quarter 2024 Financial Results
BU
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
BU
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
BU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
BU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
AQ
Gilead Sciences Announces Completion of Acquisition of CymaBay
AQ
Gilead Sciences Announces Completion of Acquisition of CymaBay
BU
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
BU
Gilead Sciences : Kite Cell Therapy Analyst & Investor Event
PU
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
BU
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
BU
Gilead's Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
AQ
Gilead Sciences, Inc. - New Real-World Data Further Support the Use of Veklury for People Hospitalized With COVID-19
AQ
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
BU
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. GILD34 Stock
  5. News Gilead Sciences, Inc.
  6. Press Releases